View ValuationCalix 将来の成長Future 基準チェック /26Calix利益と収益がそれぞれ年間55.6%と22%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-47.6% 63.4%なると予測されています。主要情報55.6%収益成長率63.39%EPS成長率Chemicals 収益成長27.9%収益成長率22.0%将来の株主資本利益率-47.57%アナリストカバレッジLow最終更新日24 Feb 2026今後の成長に関する最新情報Breakeven Date Change • Dec 24No longer forecast to breakevenThe 2 analysts covering Calix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.50m in 2028. New consensus forecast suggests the company will make a loss of AU$19.2m in 2028.Breakeven Date Change • Aug 27Forecast to breakeven in 2028The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 14% per year to 2027. The company is expected to make a profit of AU$3.60m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.Breakeven Date Change • May 03Forecast to breakeven in 2022The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$8.13m in 2022.Breakeven Date Change • Sep 18Forecast to breakeven in 2022The 3 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$845.6k in 2022. Earnings growth of 5.3% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Feb 05Calix Limited to Report First Half, 2026 Results on Feb 24, 2026Calix Limited announced that they will report first half, 2026 results on Feb 24, 2026Breakeven Date Change • Dec 24No longer forecast to breakevenThe 2 analysts covering Calix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.50m in 2028. New consensus forecast suggests the company will make a loss of AU$19.2m in 2028.お知らせ • Sep 22Calix Limited, Annual General Meeting, Nov 18, 2025Calix Limited, Annual General Meeting, Nov 18, 2025. Location: hybrid meeting, AustraliaBreakeven Date Change • Aug 27Forecast to breakeven in 2028The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 14% per year to 2027. The company is expected to make a profit of AU$3.60m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.Reported Earnings • Aug 26Full year 2025 earnings released: AU$0.096 loss per share (vs AU$0.14 loss in FY 2024)Full year 2025 results: AU$0.096 loss per share (improved from AU$0.14 loss in FY 2024). Revenue: AU$28.2m (up 17% from FY 2024). Net loss: AU$19.2m (loss narrowed 24% from FY 2024). Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 7.5% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 29Calix Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Calix Limited announced that they will report fiscal year 2025 results on Aug 26, 2025お知らせ • Dec 09Calix Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Calix Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,666,667 Price\Range: AUD 0.75New Risk • Nov 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$148.5m (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$13m net loss in 3 years). Market cap is less than US$100m (AU$148.5m market cap, or US$98.3m).お知らせ • Sep 24Calix Limited, Annual General Meeting, Nov 22, 2024Calix Limited, Annual General Meeting, Nov 22, 2024.Reported Earnings • Aug 28Full year 2024 earnings released: AU$0.14 loss per share (vs AU$0.13 loss in FY 2023)Full year 2024 results: AU$0.14 loss per share (further deteriorated from AU$0.13 loss in FY 2023). Revenue: AU$24.2m (up 30% from FY 2023). Net loss: AU$25.3m (loss widened 9.0% from FY 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 20Calix Limited to Report Fiscal Year 2024 Results on Aug 27, 2024Calix Limited announced that they will report fiscal year 2024 results on Aug 27, 2024New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$150.7m (US$97.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years). Market cap is less than US$100m (AU$150.7m market cap, or US$97.3m).New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$41m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$14m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change).Recent Insider Transactions • Mar 14Non Executive Independent Director recently bought AU$87k worth of stockOn the 12th of March, Catriona Deans bought around 50k shares on-market at roughly AU$1.73 per share. This transaction increased Catriona's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$41m free cash flow). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$14m net loss in 2 years).Reported Earnings • Feb 25First half 2024 earnings released: AU$0.07 loss per share (vs AU$0.055 loss in 1H 2023)First half 2024 results: AU$0.07 loss per share (further deteriorated from AU$0.055 loss in 1H 2023). Revenue: AU$12.2m (up 41% from 1H 2023). Net loss: AU$12.6m (loss widened 37% from 1H 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Feb 16Calix Limited to Report First Half, 2024 Results on Feb 23, 2024Calix Limited announced that they will report first half, 2024 results on Feb 23, 2024お知らせ • Dec 19Calix Limited Announces New Board Appointments, Effective 1 January 2024Calix Limited announced the appointments of Dr Sarah Ryan and Peter Dixon to the Calix board of directors as non-executive directors. Dr Ryan and Mr. Dixon's appointments will be effective from 1 January 2024. At the Calix 2022 Annual General Meeting, Calix Chair, Peter Turnbull noted the board's proactive approach to board succession and renewal to ensure the composition of the board is appropriate at all times to support the delivery of Calix's strategic goals. This process has been underway for some time and these latest appointments represent a major next step in Calix's board renewal. A further step is the expected retirement of Peter Turnbull prior to 30 June 2024, with Alison Deans set to become the new chair following Peter Turnbull's retirement. These changes will result in the Calix Board being comprised of four highly experienced non-executives and two executive directors, further enhancing the governance of the company. As a non-executive director and former senior operational executive, Dr Ryan brings extensive global engineering and commercial experience, encompassing private equity, investment management, energy sector operations, marketing, research, and team management. With a particular emphasis on innovation and technology enabled solutions, Dr Ryan has led and helped to build organizations across the energy, natural resources, and infrastructure sectors. Dr Ryan is currently a non-executive director of Viva Energy Group Limited (ASX:VEA), Aurizon Holdings Limited (ASX:AZJ), Transurban Group (ASX:TCL) and the Future Battery Industries Co- operative Research Centre. Until recently, Dr Ryan was a non-executive director of Oz Minerals Limited (ASX:OZL) and Woodside Energy Group Limited (ASX:WDS). Dr Ryan is also a Strategic Advisory Panel Member of the ARC Centre of Excellence for Green Electrochemical Transformation of Carbon Dioxide and Chair of the Energy Forum for the Australian Academy of Technological Sciences and Engineering.Dr Ryan holds a Bachelor of Science in Geology from the University of Melbourne, a Bachelor of Science (First Class Honours) in Geophysics from the University of Adelaide, and a PhD in Petroleum Geology and Geophysics from the University of Adelaide. Dr Ryan is also a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE), a Fellow of the Australian Institute of Energy, a Member of the Australian Institute of Company Directors, a Member of Women Corporate Directors, and a member of Chief Executive Women. With over 25 years of deep and diverse experience across the legal, investment banking and funds management sectors, Mr. Dixon brings expertise across corporate strategy, investment management, corporate advisory (including equity capital markets) and legal governance issues to the Calix board. Mr. Dixon is currently Chief Strategy Officer for HPX Group (which provides legal, compliance, governance and workplace services to a diverse range of clients across Australia and New Zealand), and is a non-executive director at Johns Lyng Group Limited. Mr. Dixon's investment banking and legal experience includes private legal practice experience at Mallesons Stephen Jacques in Sydney and Linklaters in London, as well as over nine years executive experience at MA Financial Group initially as an investment banker and ultimately as the group's General Counsel. Mr. Dixon also spent time earlier in his career at Macquarie Group Limited (ASX:MQG) in various roles across corporate strategy, investment management and corporate advisory. Peter's unique combination of skills and experience including in relation to complex corporate transactions and strategic options and execution will directly support Calix's strategic goals. Mr. Dixon holds a Bachelor of Commerce (Finance) and a Bachelor of Laws from the University of New South Wales. Mr. Dixon has previously been admitted to practice as a solicitor in New South Wales and in England and Wales.お知らせ • Oct 17Calix Limited, Annual General Meeting, Nov 16, 2023Calix Limited, Annual General Meeting, Nov 16, 2023, at 09:00 AUS Eastern Standard Time. Agenda: To consider remuneration report; to consider re election of Helen Fisher; to consider election of Alison Deans; to consider appointment of auditor; and to consider other matters.Reported Earnings • Aug 24Full year 2023 earnings released: AU$0.14 loss per share (vs AU$0.10 loss in FY 2022)Full year 2023 results: AU$0.14 loss per share (further deteriorated from AU$0.10 loss in FY 2022). Revenue: AU$18.6m (flat on FY 2022). Net loss: AU$23.2m (loss widened 42% from FY 2022). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 77% per year, which means it is well ahead of earnings.お知らせ • Aug 21Calix Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Calix Limited announced that they will report fiscal year 2023 results on Aug 24, 2023Reported Earnings • Feb 21First half 2023 earnings released: AU$0.055 loss per share (vs AU$0.047 loss in 1H 2022)First half 2023 results: AU$0.055 loss per share (further deteriorated from AU$0.047 loss in 1H 2022). Revenue: AU$8.63m (down 12% from 1H 2022). Net loss: AU$9.17m (loss widened 23% from 1H 2022). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 88% per year, which means it is well ahead of earnings.お知らせ • Feb 13Calix Limited to Report First Half, 2023 Results on Feb 21, 2023Calix Limited announced that they will report first half, 2023 results on Feb 21, 2023お知らせ • Jan 30Calix Limited Receives Funding from the Australian Renewable Energy Agency and from Germany's Federal Ministry of Education and ResearchCalix Limited announced that the Solar Methanol Project (the Project), of which it is a consortium member, has been awarded funding to develop the production of sustainable fuels from captured process CO2 emissions. As announced by the Hon Chris Bowen MP, Minister for Climate Change and Energy on 27 January, the "HyGATE" Solar Methanol Project has been awarded AUD 19.48 million from the Australian Renewable Energy Agency (ARENA) and 13.2 million (AUD 20.19 million) from Germany's Federal Ministry of Education and Research (BMBF) to develop a world-first green methanol demonstration plant in Port Augusta, South Australia. The Solar Methanol Project Exporting green hydrogen produced in Australia to Germany offers the promise of leveraging Australia's abundant renewable energy resources to help the decarbonisation of German industry. Methanol is a versatile hydrogen derivative and has the potential to act as an effective green hydrogen carrier. Its clean and economical synthesis could help enable the decarbonisation of hard-to-abate transport sectors such as aviation and shipping. In addition to Calix, the Solar Methanol Project consortium includes Australian cleantech company Vast Solar and leading engineering and consultancy firm Fichtner, and is supported by the Australian Solar Thermal Institute. The Project aims to integrate several innovative low emission technologies to source renewable power and process heat, green hydrogen electrolysis, and, with Calix's Leilac technology, renewably powered electric calcination of limestone and the efficient capture of unavoidable process CO2 emissions. The Project intends to renewably power a 10MW electrolyser to produce green hydrogen, and a lime plant that produces CO2 as an unavoidable process emission. The clean energy, hydrogen and CO 2 will then be used to synthesise up to 7,500 tonnes per year of green methanol to be developed for use as a sustainable transport fuel. The Project aims to be a catalyst for a solar methanol industry in Australia, with the potential to significantly scale domestic green fuel use as well as potential exports to Germany and other global markets.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 25Full year 2022 earnings released: AU$0.10 loss per share (vs AU$0.05 loss in FY 2021)Full year 2022 results: AU$0.10 loss per share (down from AU$0.05 loss in FY 2021). Revenue: AU$18.5m (down 3.9% from FY 2021). Net loss: AU$16.3m (loss widened 118% from FY 2021). Over the next year, revenue is forecast to grow 26%, compared to a 13% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 93% per year, which means it is well ahead of earnings.Breakeven Date Change • May 03Forecast to breakeven in 2022The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$8.13m in 2022.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 26First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: AU$0.047 loss per share (down from AU$0.017 loss in 1H 2021). Revenue: AU$9.82m (up 6.6% from 1H 2021). Net loss: AU$7.48m (loss widened 203% from 1H 2021). Revenue missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 34%, compared to a 20% growth forecast for the industry in Australia.Board Change • Feb 25Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Sep 18Forecast to breakeven in 2022The 3 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$845.6k in 2022. Earnings growth of 5.3% is required to achieve expected profit on schedule.Reported Earnings • Aug 26Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.05 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$19.2m (up 37% from FY 2020). Net loss: AU$9.11m (loss widened 29% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 27Revenue beats expectationsRevenue exceeded analyst estimates by 9.7%. Over the next year, revenue is forecast to grow 20%, compared to a 18% growth forecast for the Chemicals industry in Australia.Reported Earnings • Feb 26First half 2021 earnings released: AU$0.017 loss per share (vs AU$0.025 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$9.21m (up 151% from 1H 2020). Net loss: AU$2.47m (loss narrowed 30% from 1H 2020).業績と収益の成長予測CHIA:CXL - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202854-12N/A-426/30/202746-13N/A-326/30/202637-34N/A-8212/31/202531-49-26-17N/A9/30/202530-34-33-23N/A6/30/202528-19-40-29N/A3/31/202527-22-36-22N/A12/31/202426-25-33-15N/A9/30/202425-25-33-14N/A6/30/202424-25-33-14N/A3/31/202423-26-37-18N/A12/31/202322-27-41-23N/A9/30/202320-25-35-20N/A6/30/202319-23-30-17N/A3/31/202318-21-23-12N/A12/31/202217-18-17-7N/A9/30/202218-17-15-5N/A6/30/202218-16-13-4N/A3/31/202219-14-16-8N/A12/31/202120-12-19-12N/A9/30/202120-10-17-10N/A6/30/202119-7-15-8N/A3/31/202119-7-9-1N/A12/31/202020-6-26N/A9/30/202017-718N/A6/30/202014-7410N/A3/31/202010-7-33N/A12/31/20195-6-9-3N/A9/30/20194-7N/A-1N/A6/30/20193-7N/A1N/A3/31/20194-7N/A2N/A12/31/20184-6N/A4N/A9/30/20184-5N/A3N/A6/30/20184-3N/A2N/A3/31/20184-3N/A1N/A12/31/20174-2N/A0N/A9/30/20174-2N/A-1N/A6/30/20174-2N/A-2N/A6/30/201614-2N/A2N/A6/30/20157-4N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CXL今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: CXL今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: CXL今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: CXLの収益 ( 22% ) Australian市場 ( 6.2% ) よりも速いペースで成長すると予測されています。高い収益成長: CXLの収益 ( 22% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CXL 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 15:53終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Calix Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Conor O’PreyCanaccord GenuityPhilip PepeShaw and Partners Limited
Breakeven Date Change • Dec 24No longer forecast to breakevenThe 2 analysts covering Calix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.50m in 2028. New consensus forecast suggests the company will make a loss of AU$19.2m in 2028.
Breakeven Date Change • Aug 27Forecast to breakeven in 2028The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 14% per year to 2027. The company is expected to make a profit of AU$3.60m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
Breakeven Date Change • May 03Forecast to breakeven in 2022The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$8.13m in 2022.
Breakeven Date Change • Sep 18Forecast to breakeven in 2022The 3 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$845.6k in 2022. Earnings growth of 5.3% is required to achieve expected profit on schedule.
お知らせ • Feb 05Calix Limited to Report First Half, 2026 Results on Feb 24, 2026Calix Limited announced that they will report first half, 2026 results on Feb 24, 2026
Breakeven Date Change • Dec 24No longer forecast to breakevenThe 2 analysts covering Calix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.50m in 2028. New consensus forecast suggests the company will make a loss of AU$19.2m in 2028.
お知らせ • Sep 22Calix Limited, Annual General Meeting, Nov 18, 2025Calix Limited, Annual General Meeting, Nov 18, 2025. Location: hybrid meeting, Australia
Breakeven Date Change • Aug 27Forecast to breakeven in 2028The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 14% per year to 2027. The company is expected to make a profit of AU$3.60m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
Reported Earnings • Aug 26Full year 2025 earnings released: AU$0.096 loss per share (vs AU$0.14 loss in FY 2024)Full year 2025 results: AU$0.096 loss per share (improved from AU$0.14 loss in FY 2024). Revenue: AU$28.2m (up 17% from FY 2024). Net loss: AU$19.2m (loss narrowed 24% from FY 2024). Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 7.5% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 29Calix Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Calix Limited announced that they will report fiscal year 2025 results on Aug 26, 2025
お知らせ • Dec 09Calix Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Calix Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,666,667 Price\Range: AUD 0.75
New Risk • Nov 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$148.5m (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$13m net loss in 3 years). Market cap is less than US$100m (AU$148.5m market cap, or US$98.3m).
お知らせ • Sep 24Calix Limited, Annual General Meeting, Nov 22, 2024Calix Limited, Annual General Meeting, Nov 22, 2024.
Reported Earnings • Aug 28Full year 2024 earnings released: AU$0.14 loss per share (vs AU$0.13 loss in FY 2023)Full year 2024 results: AU$0.14 loss per share (further deteriorated from AU$0.13 loss in FY 2023). Revenue: AU$24.2m (up 30% from FY 2023). Net loss: AU$25.3m (loss widened 9.0% from FY 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 20Calix Limited to Report Fiscal Year 2024 Results on Aug 27, 2024Calix Limited announced that they will report fiscal year 2024 results on Aug 27, 2024
New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$150.7m (US$97.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years). Market cap is less than US$100m (AU$150.7m market cap, or US$97.3m).
New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$41m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$14m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change).
Recent Insider Transactions • Mar 14Non Executive Independent Director recently bought AU$87k worth of stockOn the 12th of March, Catriona Deans bought around 50k shares on-market at roughly AU$1.73 per share. This transaction increased Catriona's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$41m free cash flow). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$14m net loss in 2 years).
Reported Earnings • Feb 25First half 2024 earnings released: AU$0.07 loss per share (vs AU$0.055 loss in 1H 2023)First half 2024 results: AU$0.07 loss per share (further deteriorated from AU$0.055 loss in 1H 2023). Revenue: AU$12.2m (up 41% from 1H 2023). Net loss: AU$12.6m (loss widened 37% from 1H 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 16Calix Limited to Report First Half, 2024 Results on Feb 23, 2024Calix Limited announced that they will report first half, 2024 results on Feb 23, 2024
お知らせ • Dec 19Calix Limited Announces New Board Appointments, Effective 1 January 2024Calix Limited announced the appointments of Dr Sarah Ryan and Peter Dixon to the Calix board of directors as non-executive directors. Dr Ryan and Mr. Dixon's appointments will be effective from 1 January 2024. At the Calix 2022 Annual General Meeting, Calix Chair, Peter Turnbull noted the board's proactive approach to board succession and renewal to ensure the composition of the board is appropriate at all times to support the delivery of Calix's strategic goals. This process has been underway for some time and these latest appointments represent a major next step in Calix's board renewal. A further step is the expected retirement of Peter Turnbull prior to 30 June 2024, with Alison Deans set to become the new chair following Peter Turnbull's retirement. These changes will result in the Calix Board being comprised of four highly experienced non-executives and two executive directors, further enhancing the governance of the company. As a non-executive director and former senior operational executive, Dr Ryan brings extensive global engineering and commercial experience, encompassing private equity, investment management, energy sector operations, marketing, research, and team management. With a particular emphasis on innovation and technology enabled solutions, Dr Ryan has led and helped to build organizations across the energy, natural resources, and infrastructure sectors. Dr Ryan is currently a non-executive director of Viva Energy Group Limited (ASX:VEA), Aurizon Holdings Limited (ASX:AZJ), Transurban Group (ASX:TCL) and the Future Battery Industries Co- operative Research Centre. Until recently, Dr Ryan was a non-executive director of Oz Minerals Limited (ASX:OZL) and Woodside Energy Group Limited (ASX:WDS). Dr Ryan is also a Strategic Advisory Panel Member of the ARC Centre of Excellence for Green Electrochemical Transformation of Carbon Dioxide and Chair of the Energy Forum for the Australian Academy of Technological Sciences and Engineering.Dr Ryan holds a Bachelor of Science in Geology from the University of Melbourne, a Bachelor of Science (First Class Honours) in Geophysics from the University of Adelaide, and a PhD in Petroleum Geology and Geophysics from the University of Adelaide. Dr Ryan is also a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE), a Fellow of the Australian Institute of Energy, a Member of the Australian Institute of Company Directors, a Member of Women Corporate Directors, and a member of Chief Executive Women. With over 25 years of deep and diverse experience across the legal, investment banking and funds management sectors, Mr. Dixon brings expertise across corporate strategy, investment management, corporate advisory (including equity capital markets) and legal governance issues to the Calix board. Mr. Dixon is currently Chief Strategy Officer for HPX Group (which provides legal, compliance, governance and workplace services to a diverse range of clients across Australia and New Zealand), and is a non-executive director at Johns Lyng Group Limited. Mr. Dixon's investment banking and legal experience includes private legal practice experience at Mallesons Stephen Jacques in Sydney and Linklaters in London, as well as over nine years executive experience at MA Financial Group initially as an investment banker and ultimately as the group's General Counsel. Mr. Dixon also spent time earlier in his career at Macquarie Group Limited (ASX:MQG) in various roles across corporate strategy, investment management and corporate advisory. Peter's unique combination of skills and experience including in relation to complex corporate transactions and strategic options and execution will directly support Calix's strategic goals. Mr. Dixon holds a Bachelor of Commerce (Finance) and a Bachelor of Laws from the University of New South Wales. Mr. Dixon has previously been admitted to practice as a solicitor in New South Wales and in England and Wales.
お知らせ • Oct 17Calix Limited, Annual General Meeting, Nov 16, 2023Calix Limited, Annual General Meeting, Nov 16, 2023, at 09:00 AUS Eastern Standard Time. Agenda: To consider remuneration report; to consider re election of Helen Fisher; to consider election of Alison Deans; to consider appointment of auditor; and to consider other matters.
Reported Earnings • Aug 24Full year 2023 earnings released: AU$0.14 loss per share (vs AU$0.10 loss in FY 2022)Full year 2023 results: AU$0.14 loss per share (further deteriorated from AU$0.10 loss in FY 2022). Revenue: AU$18.6m (flat on FY 2022). Net loss: AU$23.2m (loss widened 42% from FY 2022). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 77% per year, which means it is well ahead of earnings.
お知らせ • Aug 21Calix Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Calix Limited announced that they will report fiscal year 2023 results on Aug 24, 2023
Reported Earnings • Feb 21First half 2023 earnings released: AU$0.055 loss per share (vs AU$0.047 loss in 1H 2022)First half 2023 results: AU$0.055 loss per share (further deteriorated from AU$0.047 loss in 1H 2022). Revenue: AU$8.63m (down 12% from 1H 2022). Net loss: AU$9.17m (loss widened 23% from 1H 2022). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 88% per year, which means it is well ahead of earnings.
お知らせ • Feb 13Calix Limited to Report First Half, 2023 Results on Feb 21, 2023Calix Limited announced that they will report first half, 2023 results on Feb 21, 2023
お知らせ • Jan 30Calix Limited Receives Funding from the Australian Renewable Energy Agency and from Germany's Federal Ministry of Education and ResearchCalix Limited announced that the Solar Methanol Project (the Project), of which it is a consortium member, has been awarded funding to develop the production of sustainable fuels from captured process CO2 emissions. As announced by the Hon Chris Bowen MP, Minister for Climate Change and Energy on 27 January, the "HyGATE" Solar Methanol Project has been awarded AUD 19.48 million from the Australian Renewable Energy Agency (ARENA) and 13.2 million (AUD 20.19 million) from Germany's Federal Ministry of Education and Research (BMBF) to develop a world-first green methanol demonstration plant in Port Augusta, South Australia. The Solar Methanol Project Exporting green hydrogen produced in Australia to Germany offers the promise of leveraging Australia's abundant renewable energy resources to help the decarbonisation of German industry. Methanol is a versatile hydrogen derivative and has the potential to act as an effective green hydrogen carrier. Its clean and economical synthesis could help enable the decarbonisation of hard-to-abate transport sectors such as aviation and shipping. In addition to Calix, the Solar Methanol Project consortium includes Australian cleantech company Vast Solar and leading engineering and consultancy firm Fichtner, and is supported by the Australian Solar Thermal Institute. The Project aims to integrate several innovative low emission technologies to source renewable power and process heat, green hydrogen electrolysis, and, with Calix's Leilac technology, renewably powered electric calcination of limestone and the efficient capture of unavoidable process CO2 emissions. The Project intends to renewably power a 10MW electrolyser to produce green hydrogen, and a lime plant that produces CO2 as an unavoidable process emission. The clean energy, hydrogen and CO 2 will then be used to synthesise up to 7,500 tonnes per year of green methanol to be developed for use as a sustainable transport fuel. The Project aims to be a catalyst for a solar methanol industry in Australia, with the potential to significantly scale domestic green fuel use as well as potential exports to Germany and other global markets.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 25Full year 2022 earnings released: AU$0.10 loss per share (vs AU$0.05 loss in FY 2021)Full year 2022 results: AU$0.10 loss per share (down from AU$0.05 loss in FY 2021). Revenue: AU$18.5m (down 3.9% from FY 2021). Net loss: AU$16.3m (loss widened 118% from FY 2021). Over the next year, revenue is forecast to grow 26%, compared to a 13% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 93% per year, which means it is well ahead of earnings.
Breakeven Date Change • May 03Forecast to breakeven in 2022The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$8.13m in 2022.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 26First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: AU$0.047 loss per share (down from AU$0.017 loss in 1H 2021). Revenue: AU$9.82m (up 6.6% from 1H 2021). Net loss: AU$7.48m (loss widened 203% from 1H 2021). Revenue missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 34%, compared to a 20% growth forecast for the industry in Australia.
Board Change • Feb 25Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Sep 18Forecast to breakeven in 2022The 3 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$845.6k in 2022. Earnings growth of 5.3% is required to achieve expected profit on schedule.
Reported Earnings • Aug 26Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.05 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$19.2m (up 37% from FY 2020). Net loss: AU$9.11m (loss widened 29% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 27Revenue beats expectationsRevenue exceeded analyst estimates by 9.7%. Over the next year, revenue is forecast to grow 20%, compared to a 18% growth forecast for the Chemicals industry in Australia.
Reported Earnings • Feb 26First half 2021 earnings released: AU$0.017 loss per share (vs AU$0.025 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$9.21m (up 151% from 1H 2020). Net loss: AU$2.47m (loss narrowed 30% from 1H 2020).